Fresenius Helios takes steps toward antitrust approval for acquisition of Rhön-Klinikum hospitals
The German antitrust authority required that three Rhön-Klinikum hospitals - in Boizenburg, Cuxhaven and Waltershausen-Friedrichroda - be excluded from the acquisition due to their geographical proximity to existing HELIOS facilities. They will remain with Rhön-Klinikum AG. Based on the authority's market assessment for the Leipzig region, HELIOS is selling two hospitals in Borna and Zwenkau, which are close to two hospitals in Leipzig that Fresenius Helios is acquiring from Rhön-Klinikum. The Borna and Zwenkau hospitals are purchased by HCM SE, a healthcare management company. Annual sales of these five hospitals are approximately €160 million.
Fresenius still expects the acquisition to be accretive to earnings per share in the first 12 months after closing, excluding one-time costs1. The acquisition is expected to be clearly accretive from the second year onwards, including one-time costs.
This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.
1 One-time costs are approximately €80 million before tax.
Fresenius AG (SE)
Fresenius is a global health care group, providing products and services for dialysis, hospitals, and outpatient medical care. In 2012, Group sales were €19.3 billion.
On September 30, 2013, the Fresenius Group had 175,249 employees worldwide.
For more information visit the Company's website at www.fresenius.com.